Thursday, July 31, 2014

Best Performing Companies To Own In Right Now

Gold’s stratospheric run during the height of the economic crisis and its aftermath served as an effective hedge against the possibility of even more disaster to come. It should hold, therefore, that gold’s collapse would signal a vote of confidence in the way markets are currently performing.

That's the scenario laid out by the famed economist Kenneth Rogoff in a blog posted to The Guardian’s website on Tuesday. So is it, in fact, what’s happening?

Yes and no, Rogoff writes, with typical academic fuzziness.

“To say that the gold market displays all of the classic features of a bubble gone bust is to oversimplify,” Rogoff (left) argues. “There is no doubt that gold's heady rise to the peak, from around $350 per ounce in July 2003, had investors drooling. The price would rise today because everyone had become convinced that it would rise even further tomorrow.”

Top 5 Gas Companies To Own In Right Now: Vishay Intertechnology Inc. (VSH)

Vishay Intertechnology Inc. designs, manufactures, and supplies discrete semiconductors and passive components. The company operates in five segments: MOSFETs, Diodes, Optoelectronic Components, Resistors & Inductors, and Capacitors. The MOSFETs segment offers low- and medium-voltage TrenchFET MOSFETs, high-voltage planar MOSFETs, high voltage Super Junction MOSFETs, power integrated circuits, and integrated function power devices. The Diodes segment provides rectifiers, small signal diodes, protection diodes, thyristors/silicon-controlled rectifiers, and power modules. The Optoelectronic Components segment offers infrared (IR) emitters and detectors, IR remote control receivers, optocouplers, solid-state relays, optical sensors, light-emitting diodes, seven-segment displays, and IR data transceiver modules. The Resistors & Inductors segment provides film, wirewound, power metal strip, variable, and non-linear resistors, as well as battery management shunts, chip fuses, ne tworks/arrays, magnetics, and connectors. The Capacitors segment offers tantalum, ceramic, film, power, heavy-current, and aluminum capacitors. The company�s semiconductor components are used for various functions, including power control, power conversion, power management, signal switching, signal routing, signal blocking, signal amplification, two-way data transfer, one-way remote control, and circuit isolation; and passive components are used to restrict current flow, suppress voltage increases, store and discharge energy, control alternating current and voltage, filter out unwanted electrical signals, and perform other functions. It serves industrial, computing, automotive, consumer, telecommunications, power supplies, military, aerospace, and medical markets. Vishay Intertechnology offers its products to the manufacturers primarily in the United States, Europe, and Asia. The company was founded in 1962 and is headquartered in Malvern, Pennsylvania.

Advisors' Opinion:
  • [By Seth Jayson]

    Vishay Intertechnology (NYSE: VSH  ) reported earnings on April 30. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 30 (Q1), Vishay Intertechnology beat expectations on revenues and beat expectations on earnings per share.

Best Performing Companies To Own In Right Now: 1-800 FLOWERS.COM Inc.(FLWS), Inc. together with its subsidiaries, operates as a florist and gift retailer in the United States. The company offers a range of products, including fresh-cut flowers, floral arrangements and plants, gifts, popcorn, gourmet foods and gift baskets, cookies, chocolates, candy, and wine through its telephonic and online sales channels, company-owned and operated retail floral stores, and franchised stores. It provides gourmet gifts, such as popcorn and specialty treats through; cookies and baked gifts through; chocolates and confections through and; gift baskets and towers through; Celebrations brand party ideas and planning tips through; and customizable invitations, announcements, and greeting cards through As of July 3, 2011, the company operated 2 floral retail stores, 1 fulfillment center, and approximately 100 franchised stores located within the United States. It has strategic online relationships with Facebook, Google, AOL, Yahoo!, and Microsoft. The company was founded in 1976 and is headquartered in Carle Place, New York.

Advisors' Opinion:

    BlueOrange Studio/Shutterstock One day out of 365, we pay homage to our sainted mothers. Those of us who are members of this long-suffering, uncomplaining, self-sacrificing class may get some soggy French toast in bed, (don't worry, kids; mom will clean up the kitchen), a chance to read in peace, or perhaps time to indulge in a long, hot bath. Bringing Home the Bacon If you really want to pay back mom for all she's done, get ready to pony up big. A card and some carnations (the official flower of Mother's Day, who knew?) just won't cut it. The cost of replacing mom as nurturer, nurse, cleaner and cook -- according to's 2014 Mother's Day salary index -- would run you $62,985 a year, up from $59,862 in 2013. Breaking down the price of having someone else handle her various duties: Cooking and cleaning, $12,230 Child care, $21,736 Homework help, $7,290 Chauffeur, $5,672 Shopping, yard work, party and activity planning, finances, etc., $15,019 And my personal favorite, finding out what the kids are up to (paid in the equivalent value of a private detective), $1,036. placed a higher value on moms in its 2014 Mother's Day salary survey, concluding that stay-at-home moms were worth $118,905 and working moms worth $70,107 (this does not include any paid salary from their job), with both groups putting more than 56 hours of overtime at home. These numbers are all up from last year's survey. Cooking It Up in a Pan Mom helps to pay for other things, too. Thanks to the Department of Agriculture, you can see what it costs to raise a child in the U.S. to 18. As of August 2013, the average cost is $241,080. This does not cover college, and hopefully dear old dad is contributing. In 2012, there were 10.3 million single U.S. mothers with children under 18, and one-third of women who gave birth in 2012 were single moms. By becoming moms, women give up time to do other things, what economists call an "opportunity cost." Particularly if your mother st

Best Performing Companies To Own In Right Now: Blackhawk Network Holdings Inc (HAWK)

Blackhawk Network Holdings, Inc., incorporated on January 27, 2006, is a prepaid payment network utilizing technology to offer a range of gift cards, other prepaid products and payment services in the United States and 18 other countries. The Company is a third-party distributor of gift. Its product offerings include gift cards, prepaid telecom products and prepaid financial services products (including general purpose reloadable (GPR), cards and its reload network). In addition, it sells physical and electronic gift cards to consumers through both online distributors and its Website, It offers gift cards from consumer brands, such as, Applebee��, iTunes, Lowe��, Macy�� and Starbucks and from payment networks, such as American Express, MasterCard and Visa. In addition, it distributes GPR, cards provided by Green Dot and NetSpend, as well as PayPower, its own GPR card. REloadit, its reload network, allows consumers to reload funds onto certain of their previously purchased GPR cards. In November 2013, Blackhawk Network Holdings Inc completed the acquisition of InteliSpend Prepaid Solutions. Effective December 2013, Blackhawk Network Holdings Inc, a unit of Safeway Inc, acquired Retailo AG.

The Company also offers prepaid solutions, including functionality and connectivity for digital wallet products within digital payments space, as well as an online gift card exchange called Cardpool. The Company�� extensive prepaid network provides benefits to its three primary constituents: consumers who purchase the products and services it offers, content providers who offer branded gift cards and other prepaid products that are redeemable for goods and services, and distribution partners who sell those products. Its extensive network connects to more than 500 content providers and over 100,000 active retail distribution locations, providing access to over 160 million consumer visits per week. For consumers, the Company provides a variety of brands and content at ! retail distribution locations and online. For its content providers, it provides access to millions of consumers and creates new customer relationships. For its distribution partners, it provides product category that drives incremental store traffic and customer loyalty. It also distributes prepaid telecom products offered by prepaid wireless telecom brands. The Company distributes its products across multiple traffic channels, such as grocery, convenience, specialty and online retailers.

Advisors' Opinion:
  • [By Ploutos]

    U.S. Stocks

    The S&P 500 (SPY) makes a new all-time high, but closes beneath that plateau for the year. The S&P 500 eclipsed its former all-time high close of 1565 on March 28th, faster than I anticipated. With the index now ending the week above 1700 for the first time, closing below 1565 for the year seems a distant memory. Not everyone was calling for a new all-time high to be reached in 2013, and investment bank equity analysts were targeting on average high single digit annual gains at the beginning of the year. I did not expect a 19.9% return through the beginning of August, but I will take it. Grade: BThe equal-weighted S&P 500 (RSP) outperforms its capitalization-weighted alternative. The equal weighted index has produced a total return of 23.34%, besting the market capitalization-weighted S&P 500. Long-time readers know that I have long extolled the virtues of equal weighting. The lagging performance of former top holding Apple (AAPL), which has 1/14th of the weight in the equal weighted index has contributed to the outperformance of the equal weighted strategy. Grade: AThe Russell 2000 (IWM) outperforms the S&P 500 as small caps outpace large caps. The Russell 2000 has bested the S&P 500 by nearly five percent with the small cap index producing an impressive 24.8% return year-to-date. Grade: AThe shares of Bank of America (BAC) outperform J.P. Morgan (JPM) and Wells Fargo (WFC) on both an absolute and risk-adjusted basis. Bank of America has outperformed the broader market, producing a 28% total return year-to-date, but it has lagged Wells Fargo (32.1%) and J.P. Morgan (31.1%) while exhibiting higher volatility. Grade: C-The banking sector (XLF) outperforms the S&P 500. The Financial Selector Sector SPDR has produced a 27.9% year-to-date, besting the S&P 500 by roughly 8%. Grade: AHomebuilders (XHB) outperform the S&P 500, but not when adjusting for their variability of returns, which is over twice that of the broad

Best Performing Companies To Own In Right Now: Koninklijke KPN NV (KPN)

Koninklijke KPN NV (KPN) is a Netherlands-based telecommunications and information and communication technology (ICT) service provider. It is divided in two business areas: the Netherlands and Mobile International. The Netherlands includes segments: Mobile Consumer, which offers voice, text and data services, and mobile wholesale; Consumer Residential, providing fixed line services; Business, responsible for wireline and wireless voice and Internet, Cloud and integrated packages for corporate clients; NETCO, which offers wireless, copper and fiber network infrastructure and services for retail and wholesale customers; and Corporate Network, which provides solutions for workspace management, connectivity, information security and data centers, cloud-based and traditional software services and consulting. Mobile International consists of segments such as Germany, Belgium, Rest of the world; and iBasis, providing wholesale voice services and terminating of international calls worldwide. Advisors' Opinion:
  • [By Corinne Gretler]

    KPN (KPN) surged 16 percent to 2.32 euros as America Movil offered 2.40 euros a share for the company. The price -- a 20 percent premium to KPN�� close yesterday -- would value the stake that America Movil doesn�� already own at 7.2 billion euros ($9.6 billion). The Mexican mobile-phone operator has a 29.8 percent holding in KPN. An agreement between the two companies to limit America Movil�� stake to 30 percent expired after KPN agreed last month to sell its German business E-Plus to Telefonica SA.

  • [By Namitha Jagadeesh]

    BP Plc and Royal Dutch Shell Plc each slipped at least 1 percent as crude declined after the U.K. parliament rejected a motion for military action against Syria. Royal KPN (KPN) NV slid 3.4 percent after America Movil SAB said it may withdraw its takeover bid if opposed by the company�� independent foundation. Hermes International SCA climbed 2.1 percent after reporting operating profit that surpassed analysts��estimates.

  • [By Corinne Gretler]

    Royal KPN NV (KPN), the former Dutch phone monopoly, surged 13 percent to 1.80 euros as three people familiar with the matter said Telefonica SA is in advanced talks to take over its German mobile-phone business.

Best Performing Companies To Own In Right Now: BioMarin Pharmaceutical Inc.(BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.

Advisors' Opinion:
  • [By Ben Levisohn]

    Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.

  • [By John Udovich]

    Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:

    Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron�� where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs�Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech�IPO Setbacks. FierceBiotech has�summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia,�slashed its asking price on 6.9 million shares to $12 a share to raise $82 million�from a range of $16 to $19 a share while�Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer,�has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming�Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its�new, patient-friendly approach for delivering inhaled nitric oxide on the
  • [By Lauren Pollock]

    BioMarin Pharmaceutical Inc.(BMRN) said a U.S. Food and Drug Administration advisory panel recommended approval of the company’s enzyme-replacement therapy for patients with a rare inherited disorder that can hinder growth. In premarket trading, shares rose 5.7% to $70.75.

Best Performing Companies To Own In Right Now: CryoLife Inc (CRY)

CryoLife, Inc. (CryoLife,), incorporated in January 19,1984, is a biological medical device company. The Company preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using CryoLife�� SynerGraft technology. The Company operates in two segments: preservation services and medical devices segment. The preservation services segment includes services revenues from the preservation of cardiac and vascular tissues during the year ended December 31, 2011. The medical devices segment includes revenues from product sales of BioGlue, BioFoam, PerClot, HemoStase and revascularization technologies, as well as sales of other medical devices. CryoLife�� surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam) and PerClot, an absorbable powdered hemostat. In May 2011, it acquired Cardiogenesis Corporation. In May 2012, the Company acquired Hemosphere, Inc. Hemosphere develops and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. In February 2014, CryoLife Inc announced the establishment of CryoLife Asia Pacific Pte. Ltd.

CryoLife distributes preserved human cardiac and vascular tissues to implanting institutions throughout the United States (U.S), Canada and Europe. CryoLife processes and preserves cardiac and vascular tissues using processing and freezing techniques, or cryopreservation. The Company�� preservation process involves the recovery of tissue from deceased human donors by tissue banks and organ procurement organizations (OTPOs), the delivery, of such tissue to the Company, the s! creening, dissection, disinfection, processing, and preservation of the tissue by the Company, and the storage and shipment of the preserved tissue.

The human heart valves and cardiac patch tissues preserved by the Company are used in cardiac reconstruction and heart valve replacement surgeries. The Company preserves human aortic and pulmonary heart valves for implantation by cardiac surgeons. In addition, the Company preserves human cardiac patches for surgeons. The Company preserves human cardiac patches in three primarily anatomic configurations: pulmonary hemi-artery, pulmonary trunk and pulmonary branch. As of December 31, 2011, CryoLife shipped approximately 77,600 heart valves and cardiac patch tissues, including approximately 3,000 shipments during 2011.

The human vascular tissues preserved by the Company, including the CryoVein and CryoArtery, are used to treat a variety of vascular reconstructions, such as peripheral bypass, hemodialysis access and aortic infections. The Company preserves small diameter human saphenous vein conduits (3 millimeter to 6 millimeter) for use in peripheral vascular reconstructions. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass, hemodialysis access, or reconstruction within infected surgical areas. As of December 31, 2011, the Company shipped approximately 66,100 human vascular tissues, including approximately 4,500 shipments during 2011.

CryoLife�� product BioGlue, designed for cardiac, vascular, pulmonary, and general surgical applications, is a polymer based on bovine blood protein and an agent for cross-linking proteins. CryoLife distributes BioGlue throughout the United States and approximately 75 other countries. CryoLife distributes BioGlue for repair of soft tissues under conformite Europeene Mark Product Certification (CE Mark). CryoLife distributes BioGlue in Japan for use in the repair of aortic dissections.

CryoLife�� product, BioFoam, is a protein hydr! ogel biom! aterial with an expansion agent, which generates a mixed-cell foam. The foam creates a mechanical barrier to decrease blood flow and develops pores for the blood to enter, leading to cellular aggregation and enhanced hemostasis. CryoLife distributes BioFoam under CE Mark certification.

CryoLife�� product, PerClot, is an absorbable, powdered hemostatic agent used in surgery. PerClot particles have a molecular structure that absorbs water from blood, creating a high concentration of platelets, red blood cells, and coagulation proteins at the bleeding site, which accelerates the physiologic clotting cascade. PerClot is readily dissolved by saline irrigation and is totally absorbed within several days. PerClot is available in one gram, three gram and five gram sizes with a 100 millimeter or 200 millimeter applicator tip. PerClot Laparoscopic is available in one gram and three gram sizes with a 380 millimeter applicator tip.

The Company competes with St. Jude Medical, Inc., Medtronic, Inc., Edwards Life Sciences, Inc., Neovasc, Inc., LifeNet Health, Inc. W.L. Gore & Associates��Propaten, C.R. Bard, Inc., Hancock Jaffe Laboratories, Inc., Maquet, Inc., CorMatrix Cardiovascular, Inc., Baxter International, Inc., Johnson & Johnson Company, Covidien Ltd, NeoMend, Inc., Pfizer, Inc., Orthovita, Inc., King Pharmaceuticals, Inc., Ethicon, Inc., ZymoGenetics, Inc. and Nycomed.

Advisors' Opinion:
  • [By Eric Volkman]

    CryoLife (NYSE: CRY  ) is putting some zip into its shares with a dividend boost. The company has declared a fresh quarterly distribution of $0.0275 per share, to be paid on June 21 to shareholders of record as of June 14. This marks the company's first-ever dividend increase -- the new amount is 10% higher than its three prior (and only) payouts, each of which totaled $0.025.

No comments:

Post a Comment